Back to Search
Start Over
A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice
- Source :
- PLoS Neglected Tropical Diseases, PLoS Neglected Tropical Diseases, Vol 12, Iss 1, p e0006191 (2018)
- Publication Year :
- 2017
-
Abstract
- Background Dengue is one of the fastest spreading vector-borne diseases, caused by four antigenically distinct dengue viruses (DENVs). Antibodies against DENVs are responsible for both protection as well as pathogenesis. A vaccine that is safe for and efficacious in all people irrespective of their age and domicile is still an unmet need. It is becoming increasingly apparent that vaccine design must eliminate epitopes implicated in the induction of infection-enhancing antibodies. Methodology/principal findings We report a Pichia pastoris-expressed dengue immunogen, DSV4, based on DENV envelope protein domain III (EDIII), which contains well-characterized serotype-specific and cross-reactive epitopes. In natural infection<br />Author summary Dengue is mosquito-borne viral disease which is currently a global public health problem. It is caused by four different types of dengue viruses. Nearly a 100 million people a year suffer from overt sickness, which may range from mild fever to potentially fatal disease. A virus-based dengue vaccine was launched for the first time in late 2015. Unexpectedly, this vaccine mimics the dengue viruses in that it appears to elicit disease-enhancing antibodies. To reduce such risk, safer vaccines that eliminate viral proteins responsible for undesirable antibodies are needed. We focused our attention on a small domain of the dengue virus surface protein known as envelope domain III (EDIII). Humans make only a small amount of antibodies against EDIII, but these antibodies are effective in blocking dengue virus from entering cells. We used a yeast expression system to display EDIIIs of all four types of dengue viruses on the surface of non-infectious virus-like particles (VLPs). These VLPs elicited antibodies, in mice and monkeys, which blocked all four dengue virus types and their variants from entering cells in culture. Importantly, these antibodies did not enhance dengue infection in a mouse model.
- Subjects :
- 0301 basic medicine
RNA viruses
Viral Diseases
Immunogen
Physiology
viruses
Dengue virus
Monkeys
medicine.disease_cause
Antibodies, Viral
Pathology and Laboratory Medicine
Biochemistry
Epitope
Pichia
Mice
Virus-like particle
Viral Envelope Proteins
Immune Physiology
Medicine and Health Sciences
Enzyme-Linked Immunoassays
Neutralizing antibody
Mammals
Vaccines
Immune System Proteins
biology
lcsh:Public aspects of medicine
virus diseases
Eukaryota
Recombinant Proteins
3. Good health
Body Fluids
Blood
Infectious Diseases
Medical Microbiology
Viral Pathogens
Vertebrates
Viruses
Anatomy
Pathogens
Macaque
Research Article
Primates
lcsh:Arctic medicine. Tropical medicine
Infectious Disease Control
medicine.drug_class
lcsh:RC955-962
030106 microbiology
Immunology
Monoclonal antibody
Serogroup
Research and Analysis Methods
Microbiology
Antibodies
03 medical and health sciences
Old World monkeys
medicine
Animals
Antibody-dependent enhancement
Severe Dengue
Vaccines, Virus-Like Particle
Viremia
Antigens
Immunoassays
Microbial Pathogens
Dengue vaccine
Flaviviruses
Public Health, Environmental and Occupational Health
Organisms
Biology and Life Sciences
Proteins
lcsh:RA1-1270
Dengue Virus
Blood Serum
Virology
Antibodies, Neutralizing
Antibody-Dependent Enhancement
Survival Analysis
Disease Models, Animal
030104 developmental biology
Amniotes
biology.protein
Immunologic Techniques
Macaca
Immune Serum
Subjects
Details
- ISSN :
- 19352735
- Volume :
- 12
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- PLoS neglected tropical diseases
- Accession number :
- edsair.doi.dedup.....880f520f4f920c1cff2920a336796b62